Lineage Cell Therapeutics, Inc. Announced the appointment of Kevin L. Cook as Chief Financial Officer. Mr. Cook brings broad expertise across a range of financial matters and has executed over $30 billion of capital raising and corporate development transactions, approximately half of which involved life sciences companies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9141 USD | -0.90% | +2.71% | -16.14% |
21/05 | Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium | CI |
09/05 | Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.14% | 17Cr | |
+38.36% | 5.27TCr | |
+39.07% | 3.9TCr | |
-8.63% | 3.85TCr | |
+25.46% | 3.04TCr | |
-11.17% | 2.64TCr | |
+11.44% | 2.61TCr | |
+45.09% | 1.42TCr | |
+32.93% | 1.26TCr | |
-5.30% | 1.15TCr |
- Stock Market
- Equities
- LCTX Stock
- News Lineage Cell Therapeutics, Inc.
- Lineage Cell Therapeutics, Inc. Appoints Kevin L. Cook as CFO